HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krych-Goldberg, M. Articles by Atkinson, J. P. Search for Related Content PubMed PubMed Citation Articles by Krych-Goldberg, M. Articles by Atkinson, J. P. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 44, 31160-31168, October 29, 1999

Decay Accelerating Activity of Complement Receptor Type 1 (CD35)
TWO ACTIVE SITES ARE REQUIRED FOR DISSOCIATING C5 CONVERTASES

Malgorzata Krych-Goldberg, Richard E. Hauhart, V. Bala Subramanian, Basil M. Yurcisin II, Daniel L. Crimmins^§, Dennis E. Hourcade, and John P. Atkinson

From the  Division of Rheumatology, Department of Medicine and the ^§ Division of Laboratory Medicine, Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110

The goal of this study was to identify the site(s) in CR1 that mediate the dissociation of the C3 and C5 convertases. To that end, truncated derivatives of CR1 whose extracellular part is composed of 30 tandem repeating modules, termed complement control protein repeats (CCPs), were generated. Site 1 (CCPs 1-3) alone mediated the decay acceleration of the classical and alternative pathway C3 convertases. Site 2 (CCPs 8-10 or the nearly identical CCPs 15-17) had one-fifth the activity of site 1. In contrast, for the C5 convertase, site 1 had only 0.5% of the decay accelerating activity, while site 2 had no detectable activity. Efficient C5 decay accelerating activity was detected in recombinants that carried both site 1 and site 2. The activity was reduced if the intervening repeats between site 1 and site 2 were deleted. The results indicate that, for the C5 convertases, decay accelerating activity is mediated primarily by site 1. A properly spaced site 2 has an important auxiliary role, which may involve its C3b binding capacity. Moreover, using homologous substitution mutagenesis, residues important in site 1 for dissociating activity were identified. Based on these results, we generated proteins one-fourth the size of CR1 but with enhanced decay accelerating activity for the C3 convertases.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				A. Yamaguchi, H. Takagawa, H. Iwakaji, S. Miyagawa, P.-C. Wang, and N. Ishii Construction of the Plasmid, Expression by Chinese Hamster Ovary Cell, Purification and Characterization of the First Three Short Consensus Repeat Modules of Human Complement Receptor Type 1 J. Biochem., April 1, 2009; 145(4): 533 - 542. [Abstract] [Full Text] [PDF]

				M. Okroj, L. Mark, A. Stokowska, S. W. Wong, N. Rose, D. J. Blackbourn, B. O. Villoutreix, O. B. Spiller, and A. M. Blom Characterization of the Complement Inhibitory Function of Rhesus Rhadinovirus Complement Control Protein (RCP) J. Biol. Chem., January 2, 2009; 284(1): 505 - 514. [Abstract] [Full Text] [PDF]

				L. Kuttner-Kondo, D. E. Hourcade, V. E. Anderson, N. Muqim, L. Mitchell, D. C. Soares, P. N. Barlow, and M. E. Medof Structure-based Mapping of DAF Active Site Residues That Accelerate the Decay of C3 Convertases J. Biol. Chem., June 22, 2007; 282(25): 18552 - 18562. [Abstract] [Full Text] [PDF]

				K. J. Katschke Jr., K. Y. Helmy, M. Steffek, H. Xi, J. Yin, W. P. Lee, P. Gribling, K. H. Barck, R. A.D. Carano, R. E. Taylor, et al. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis J. Exp. Med., June 11, 2007; 204(6): 1319 - 1325. [Abstract] [Full Text] [PDF]

				C. L. Harris, D. M. Pettigrew, S. M. Lea, and B. P. Morgan Decay-Accelerating Factor Must Bind Both Components of the Complement Alternative Pathway C3 Convertase to Mediate Efficient Decay J. Immunol., January 1, 2007; 178(1): 352 - 359. [Abstract] [Full Text] [PDF]

				M. K. Liszewski, M. K. Leung, R. Hauhart, R. M. L. Buller, P. Bertram, X. Wang, A. M. Rosengard, G. J. Kotwal, and J. P. Atkinson Structure and Regulatory Profile of the Monkeypox Inhibitor of Complement: Comparison to Homologs in Vaccinia and Variola and Evidence for Dimer Formation J. Immunol., March 15, 2006; 176(6): 3725 - 3734. [Abstract] [Full Text] [PDF]

				M. Krych-Goldberg, R. E. Hauhart, T. Porzukowiak, and J. P. Atkinson Synergy between Two Active Sites of Human Complement Receptor Type 1 (CD35) in Complement Regulation: Implications for the Structure of the Classical Pathway C3 Convertase and Generation of More Potent Inhibitors J. Immunol., October 1, 2005; 175(7): 4528 - 4535. [Abstract] [Full Text] [PDF]

				J. Mullick, A. K. Singh, Y. Panse, V. Yadav, J. Bernet, and A. Sahu Identification of Functional Domains in Kaposica, the Complement Control Protein Homolog of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) J. Virol., May 1, 2005; 79(9): 5850 - 5856. [Abstract] [Full Text] [PDF]

				L. A. Kuttner-Kondo, M. P. Dybvig, L. M. Mitchell, N. Muqim, J. P. Atkinson, M. E. Medof, and D. E. Hourcade A Corresponding Tyrosine Residue in the C2/Factor B Type A Domain Is a Hot Spot in the Decay Acceleration of the Complement C3 Convertases J. Biol. Chem., December 26, 2003; 278(52): 52386 - 52391. [Abstract] [Full Text] [PDF]

				K. Yazdanbakhsh, S. Kang, D. Tamasauskas, D. Sung, and A. Scaradavou Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy Blood, June 15, 2003; 101(12): 5046 - 5052. [Abstract] [Full Text] [PDF]

				L. A. Kuttner-Kondo, L. Mitchell, D. E. Hourcade, and M. E. Medof Characterization of the Active Sites in Decay-Accelerating Factor J. Immunol., August 15, 2001; 167(4): 2164 - 2171. [Abstract] [Full Text] [PDF]

				J. M. Moulds, P. A. Zimmerman, O. K. Doumbo, L. Kassambara, I. Sagara, D. A. Diallo, J. P. Atkinson, M. Krych-Goldberg, R. E. Hauhart, D. E. Hourcade, et al. Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1 Blood, May 1, 2001; 97(9): 2879 - 2885. [Abstract] [Full Text] [PDF]

				J. A. Rowe, S. J. Rogerson, A. Raza, J. M. Moulds, M. D. Kazatchkine, K. Marsh, C. I. Newbold, J. P. Atkinson, and L. H. Miller Mapping of the Region of Complement Receptor (CR) 1 Required for Plasmodium falciparum Rosetting and Demonstration of the Importance of CR1 in Rosetting in Field Isolates J. Immunol., December 1, 2000; 165(11): 6341 - 6346. [Abstract] [Full Text] [PDF]

				M. K. Liszewski, M. Leung, W. Cui, V. B. Subramanian, J. Parkinson, P. N. Barlow, M. Manchester, and J. P. Atkinson Dissecting Sites Important for Complement Regulatory Activity in Membrane Cofactor Protein (MCP; CD46) J. Biol. Chem., November 22, 2000; 275(48): 37692 - 37701. [Abstract] [Full Text] [PDF]

				D. E. Hourcade, L. Mitchell, L. A. Kuttner-Kondo, J. P. Atkinson, and M. E. Medof Decay-accelerating Factor (DAF), Complement Receptor 1 (CR1), and Factor H Dissociate the Complement AP C3 Convertase (C3bBb) via Sites on the Type A Domain of Bb J. Biol. Chem., January 4, 2002; 277(2): 1107 - 1112. [Abstract] [Full Text] [PDF]